If you have been reading about DPP-4 resistance and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-13. Numbers and descriptions here follow the published literature rather than marketing material.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | free base, without counter-ion |
| Molecular weight | About 4114 Da | peptide backbone plus attached lipid chain |
| Plasma half-life | About 165 hours | supports once-weekly dosing in humans |
| Plasma protein binding | Greater than 99 percent | attributed mainly to serum albumin |
| Receptor target | GLP-1 receptor | Gs-coupled, raises intracellular cyclic AMP |
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Two principal therapeutic variants exist under separate regulatory filings, one indicated for glycemic control in type 2 diabetes and one for chronic weight management. Both use the same active molecule; differences lie in formulation strength, titration schedule, and labeling. Regulatory agencies in the United States and European Union approved injectable forms in 2017 and 2018 respectively. An oral tablet formulation received approval later, using a carrier molecule to enhance absorption across the gastric epithelium. Labeling differs by jurisdiction and by indication.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
== External links == A Detailed Glycolysis Animation provided by IUBMB (Adobe Flash Required) The Glycolytic enzymes in Glycolysis at RCSB PDB Glycolytic cycle with animations at wdv.com Metabolism, Cellular Respiration and Photosynthesis – The Virtual Library of Biochemistry, Molecular Biology and Cell Biology The chemical logic behind glycolysis at ufp.pt Expasy biochemical pathways poster Archived 2010-06-20 at the Wayback Machine at ExPASy MedicalMnemonics.com: 317 5468 metpath: Interactive representation of glycolysis Archived 2015-04-02 at the Wayback Machine
=== Cost === The recognised metalloids and their closer neighbours mostly cost less than silver; only polonium and astatine are more expensive than gold, on account of their significant radioactivity. As of 5 April 2014, prices for small samples (up to 100 g) of silicon, antimony and tellurium, and graphite, aluminium and selenium, average around one third the cost of silver (US$1.5 per gram or about $45 an ounce). Boron, germanium, and arsenic samples average about three-and-a-half times the cost of silver. Polonium is available for about $100 per microgram. Zalutsky and Pruszynski estimate a similar cost for producing astatine. Prices for the applicable elements traded as commodities tend to range from two to three times cheaper than the sample price (Ge), to nearly three thousand times cheaper (As).
The Good Food Award Television and Radio Personality – 1995/1996 The England for Excellence Awards – Outstanding Contribution to Tourism Award – 1988–1998 Caterer and Hotelkeeper 1999 Chef Award – Chef of the Year The Catey Awards AA Guide Chefs' Chef of the Year 1999–2000 Waterford Wedgwood Hospitality Award – 1999 The Glenfiddich Trophy – 2001 The Cornwall Tourist Award – A special award for outstanding services to Cornwall 2002 OBE – 2003 New Year Honours: For services to tourism in Cornwall CatererSearch 100 – 14th most influential chef in UK in 2005 In 2012, Stein was among the British cultural icons selected by pop artist Sir Peter Blake to appear in a new version of his most famous artwork – the Beatles' Sgt. Pepper's Lonely Hearts Club Band album cover – to celebrate the British cultural figures of the last six decades. 5 July 2016, Rick and Jill Stein received the Special Award at the prestigious Catey Awards, for their more than 41 years of outstanding contribution to the hospitality industry. CBE – 2018 New Year Honours: For services to the economy
== Further reading == Collip, James (May 1941). "Frederick Grant Banting, Discoverer of Insulin". The Scientific Monthly. 52 (5): 472–474. Bibcode:1941SciMo..52..472C. JSTOR 17312. Banting, F.G. & Best, C.H. (1922), "The Internal Secretions of the Pancreas", The Journal of Laboratory and Clinical Medicine, Vol.7, No.5, (February 1922), pp. 251–266. Banting, F.G., Best, C.H., Collip, J.B., Campbell, W.R. & Fletcher, A.A. (1922), "Pancreatic Extracts in the Treatment of Diabetes Mellitus", The Canadian Medical Association Journal, Vol.12, No.3, (March 1922), pp.141–146. US patent no.1,469,994 (held by "Frederick G. Banting and Charles Herbert Best, of Toronto, Ontario, and James Bertram Collip of Edmonton, Alberta, Canada"), (filed: 12 January 1923), (patented: 9 October 1923), for "Extract Obtainable from the Mammalian Pancreas or from the Related Glands in Fishes, Useful in the Treatment of Diabetes Mellitus, and a Method of Preparing it". Best, C. H. (November 1, 1942). "Frederick Grant Banting 1891–1941". Obituary Notices of Fellows of the Royal Society. 4 (11): 20–26. doi:10.1098/rsbm.1942.0003. S2CID 162239410. Bliss, Michael (1992) [1984]. Banting: A Biography. Toronto, Ontario: University of Toronto Press. ISBN 978-0-8020-7387-7. Banting, F. G.; Best, C. H. (2009). "The Journal of Laboratory and Clinical Medicine: Vol. VII St. Louis, February, 1922 No. 5". Nutrition Reviews. 45 (4): 55–57. doi:10.1111/j.1753-4887.1987.tb07442.x. PMID 3550540. Bliss, Michael (1990) [1982]. The Discovery of Insulin (3rd ed.). University of Toronto Press. ISBN 978-0-8020-8344-9.
Sources: en.wikipedia.org
== See also == Cannabis in Spain Crime and violence in Latin America CIA drug trafficking allegations Illegal drug trade in the Philippines Illegal drug trade in Bolivia Maritime drug trafficking in Latin America United Nations Office on Drugs and Crime United Nations Commission on Narcotic Drugs 2025 livestreamed murder in Argentina
== Atomic spectroscopy == Electrons exist in energy levels (i.e. atomic orbitals) within an atom. Atomic orbitals are quantized, meaning they exist as defined values instead of being continuous (see: atomic orbitals). Electrons may move between orbitals, but in doing so they must absorb or emit energy equal to the energy difference between their atom's specific quantized orbital energy levels. In optical spectroscopy, energy absorbed to move an electron to a higher energy level (higher orbital) and/or the energy emitted as the electron moves to a lower energy level is absorbed or emitted in the form of photons (light particles). Because each element has a unique number of electrons, an atom will absorb/release energy in a pattern unique to its elemental identity (e.g. Ca, Na, etc.) and thus will absorb/emit photons in a correspondingly unique pattern. The type of atoms present in a sample, or the amount of atoms present in a sample can be deduced from measuring these changes in light wavelength and light intensity. Atomic spectroscopy is further divided into atomic absorption spectroscopy and atomic emission spectroscopy. In atomic absorption spectroscopy, light of a predetermined wavelength is passed through a collection of atoms. If the wavelength of the source light has energy corresponding to the energy difference between two energy levels in the atoms, a portion of the light will be absorbed. The difference between the intensity of the light emitted from the source (e.g., lamp) and the light collected by the detector yields an absorbance value.
Later in August, Gorbachev resigned as general secretary of the Communist party, and Russian President Boris Yeltsin ordered the seizure of Soviet property. Gorbachev clung to power as the President of the Soviet Union until 25 December 1991, when the USSR dissolved. Fifteen states emerged from the Soviet Union, with by far the largest and most populous one (which also was the founder of the Soviet state with the October Revolution in Petrograd), the Russian Federation, taking full responsibility for all the rights and obligations of the USSR under the Charter of the United Nations, including the financial obligations. As such, Russia assumed the Soviet Union's UN membership and permanent membership on the Security Council, nuclear stockpile and the control over the armed forces. In his 1992 State of the Union Address, US President George H. W. Bush expressed his emotions: "The biggest thing that has happened in the world in my life, in our lives, is this: By the grace of God, America won the Cold War." Bush and Yeltsin met in February 1992, declaring a new era of "friendship and partnership". In January 1993, Bush and Yeltsin agreed to START II, which provided for further nuclear arms reductions on top of the original START treaty.
Sources: en.wikipedia.org
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.
Albumin is the most abundant protein in plasma and carries molecules that bear fatty-acid chains. Binding shields the peptide from renal filtration and from peptidases, keeping a circulating reservoir. Slow release from this reservoir produces sustained receptor occupancy and supports infrequent dosing.
The insulinotropic effect is glucose-dependent, meaning secretion increases mainly when glucose is elevated. This property is often described as lowering the chance of hypoglycaemia when the compound is used alone. Other glucose-lowering agents used at the same time can still cause low blood glucose.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.